Clinical Scorecard: Assessment of Early Risk Factors and Temporal Biomarker Trends in Cerebral Infarction Associated with Trousseau Syndrome in Lung Cancer Patients
At a Glance
Category
Detail
Condition
Key Mechanisms
Hypercoagulable state associated with malignancy, particularly lung cancer.
Target Population
Care Setting
Key Highlights
Developed a five-variable model for early risk stratification of TSCI.
Model demonstrated good discrimination (AUC = 0.861).
Fulminant TSCI showed significant abnormalities in coagulation and inflammatory markers.
Temporal biomarker patterns indicated differences between early and late-onset TSCI.
Guideline-Based Recommendations
Diagnosis
Utilize a five-variable model including serum magnesium, INR, prothrombin time, albumin-to-globulin ratio, and history of hypertension for TSCI risk assessment.
Management
Consider early anticoagulation strategies in high-risk lung cancer patients.
Monitoring & Follow-up
Regular monitoring of coagulation and inflammatory markers in patients with lung cancer.
Risks
High recurrence rates of TSCI and associated mortality.
Patient & Prescribing Data
Lung cancer patients with or at risk for Trousseau syndrome-related cerebral infarction.
Clinical Best Practices
Implement routine screening for TSCI risk factors in lung cancer patients.
